Download PDF
Thromb Haemost 1986; 55(01): 078-085
DOI: 10.1055/s-0038-1661452
Original Article
Schattauer GmbH Stuttgart

Tissue Thromboplastin Induced Reversible DIC and Heparin-Enhanced Inhibitors in Dogs

German A Marbet
The Center for Thrombosis and Hemostasis, Division of Hematology, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, USA
,
Michael J Griffith
The Center for Thrombosis and Hemostasis, Division of Hematology, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, USA
› Author Affiliations
Further Information

Publication History

Received 17 May 1985

Accepted 08 November 1985

Publication Date:
19 July 2018 (online)

  PDF Download  Permissions and Reprints

Summary

Reversible acute disseminated intravascular coagulation (DIC) has been induced in dogs by intravenous injection of homologous tissue thromboplastin. There was no measurable consumption of antithrombin III and heparin cofactor II even if fibrinogen was reduced during DIC by more than 80% of its baseline. The prothrombin level remained practically constant. These data correspond to the generation of a few nanomoles of thrombin in vivo with subsequent pseudo-first order inactivation by the major thrombin inhibitors. An ex vivo measure of the pseudo-first order rate constant (dynamic thrombin inhibitory capacity, DTIC) was a sensitive probe of circulating heparin. There was no change of DTIC during DIC in the absence of exogenous heparin suggesting that heparin-like endogenous glycosaminoglycans were not released in substantial amounts. Pretreatment with heparin efficiently inhibited the development of tissue thromboplastin induced DIC. This animal model may serve as a tool for the study of glycosaminoglycan anticoagulants in vivo.

Key words

Reversible DIC in dogs - Antithrombin III - Heparin cofactor II - Glycosaminoglycans
 

  • References

  • 1 Rosenberg RD. Heparin-Antithrombin-System. In: Hemostasis and Thrombosis. Basic Principles and Clinical Practice. Colman RW, Hirsh J, Marder VJ, Salzman EW. (eds.) J B Lippincott Company; Philadelphia, Toronto: 1982
    Google Scholar
  • 2 Barrowcliffe TW, Thomas DP. Antithrombin III and heparin. In: Haemostasis and Thrombosis. Bloom AL, Thomas DP. (eds.) Churchill Livingstone; Edingburgh: 1981
    Google Scholar
  • 3 Egeberg O. Inherited antithrombin deficiency causing thrombophilia. Thrombos Diathes Haemorrh 1965; 13: 516-530
    PubMedGoogle Scholar
  • 4 Briginshaw GF, Shanberge JN. Identification of two distinct heparin cofactors in human plasma: I. Separation and partial purification. Arch Biochem Biophys 1974; 161: 683-690
    CrossrefPubMedGoogle Scholar
  • 5 Briginshaw GF, Shanberger JN. Identification of two distinct heparin cofactors in human plasma: II. Inhibition of thrombin and activated factorX. Thromb Res 1974; 4: 463-477
    CrossrefPubMedGoogle Scholar
  • 6 Tollefsen DM, Blank MK. Detection of a new heparin dependent inhibitor of thrombin in human plasma. J Clin Invest 1981; 68: 589-596
    CrossrefPubMedGoogle Scholar
  • 7 Griffith MJ, Carraway T, White GC, Dombrose FA. Heparin cofactor activities in a family with hereditary antithrombin III deficiency: Evidence for a second heparin cofactor in human plasma. Blood 1983; 61: 111-118
    PubMedGoogle Scholar
  • 8 Jordan RE, Oosta GM, Gardner WT, Rosenberg RD. The kinetics of hemostatic enzyme antithrombin interactions in the presence of low molecular weight heparin. J Biol Chem 1980; 255: 10081-10090
    PubMedGoogle Scholar
  • 9 Jordan R, Beeler D, Rosenberg R. Fractionation of low molecular weight heparin species and their interaction with antithrombin. J Biol Chem 1979; 254: 2902-2913
    PubMedGoogle Scholar
  • 10 Griffith MJ. Measurement of the heparin enhanced antithrombin III/ thrombin reaction rate in the presence of synthetic substrates. Thromb Res 1982; 25: 245-253
    CrossrefPubMedGoogle Scholar
  • 11 Tollefsen DM, Majerus DW, Blank MK. Heparin cofactor II. Purification and properties of a heparin-dependent inhibitor of thrombin in human plasma. J Biol Chem 1982; 257: 2162-2169
    PubMedGoogle Scholar
  • 12 Tollefsen DM, Pestka CA, Monafo WJ. Activation of heparin cofactor II by dermatan sulfate. J Biol Chem 1983; 258: 6713-6716
    PubMedGoogle Scholar
  • 13 Griffith MJ, Marbet GA. Dermatan sulfate and heparin can be fractionated by affinity for heparin cofactor II. Biochem Biophys Res Commun 1983; 112: 663-670
    CrossrefPubMedGoogle Scholar
  • 14 Downing MR, Bloom JW, Mann KG. Comparison of the inhibition of thrombin by three plasma protease inhibitors. Biochemistry 1978; 17: 2649-2653
    CrossrefPubMedGoogle Scholar
  • 15 Penick GD, Roberts HR, Webster WP, Brinkhous KM. Hemorrhagic states secondary to intravascular clotting. Arch Path 1958; 66: 709-714
    PubMedGoogle Scholar
  • 16 Gurewich V, Nunn T, Lipinski B. Activation of intrinsic or extrinsic blood coagulation in experimental venous thrombosis and disseminated intravascular coagulation: pathogenetic differences. Thromb Res 1979; 14: 931-940
    CrossrefPubMedGoogle Scholar
  • 17 Collen D, Matsuo O, Stassen JM, Kettner C, Shaw S. In vivo studies of a synthetic inhibitor of thrombin. J Lab Clin Med 1982; 99: 76-83
    PubMedGoogle Scholar
  • 18 Owen CA, Mann KG, McDuffie FC. The turnover in normal dogs of prothrombin and its fragments, effect of induced intravascular coagulation. Thromb Haemostas 1979; 42: 548-555
    PubMedGoogle Scholar
  • 19 Bick RL, Bick MD, Fekete LF. Antithrombin III patterns in disseminated intravascular coagulation. Am J Clin Pathol 1980; 73: 577-583
    CrossrefPubMedGoogle Scholar
  • 20 Lammle B, Tran TH, Ritz R, Duckert F. Plasma prekallikrein, factor XII, antithrombin III, Q-inhibitor and a2-macroglobulin in critically ill patients with suspected disseminated intravascular coagulation (DIC). Am J Clin Pathol 1984; 82: 396-404
    CrossrefPubMedGoogle Scholar
  • 21 Cooper HA, Bowie EJW, Owen CA. Chronic induced intravascular coagulation in dogs. Am J. Physiol 1973; 225: 1355-1358
    PubMedGoogle Scholar
  • 22 Smith HP, Warner ED, Brinkhous KM. Prothrombin deficiency and the bleeding tendency in liver injury (chloroform intoxication). J Exp Med 1937; 66: 801-811
    CrossrefPubMedGoogle Scholar
  • 23 Griffith MJ. Kinetics of the heparin-enhanced antithrombin III/ thrombin reaction. J Biol Chem 1982; 257: 7360-7365
    PubMedGoogle Scholar
  • 24 Clauss A. Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens. Acta haematol (Basel) 1957; 17: 237-246
    CrossrefPubMedGoogle Scholar
  • 25 Blomback B, Blomback M. Purification of human and bovine fibrinogen. Ark Kemi 1956; 10: 415-443
    PubMedGoogle Scholar
  • 26 Teger-Nielsson AC, Friberger P, Gyzander E. Determination of a new rapid plasmin inhibitor in human blood by means of a plasmin specific tripeptide substrate. Scand J Clin Lab Invest 1977; 37: 203-409
    PubMedGoogle Scholar
  • 27 Morita T, Iwanaga S, Suzuki T. The mechanism of activation of bovine prothrombin by an activator isolated from Echis carinatus venom and characterization of the new active intermediates. J Biochem 1976; 79: 1089-1108
    CrossrefPubMedGoogle Scholar
  • 28 Briet E, Noyes CM, Roberts HR, Griffith MJ. Cleavage and activation of human prothrombin by Echis carinatus venom. Throm-bos Res 1982; 27: 591-600
    CrossrefPubMedGoogle Scholar
  • 29 Kirchhof BRJ, Vermeer C, Hemker HC. The determination of prothrombin using synthetic chromogenic substrates, choice of a suitable activator. Thromb Res 1978; 13: 219-232
    CrossrefPubMedGoogle Scholar
  • 30 Snedecor GW, Cochran WG. Statistical Methods, 6th edition. Ames, Iowa, USA 1978
    PubMedGoogle Scholar
  • 31 Martinelli RA, Scheraga HA. Steady state kinetic study of the bovine thrombin-fibrinogen interaction. Biochemistry 1980; 19: 2343-2350
    CrossrefPubMedGoogle Scholar
  • 32 Bando M, Matsushima A, Hirano J, Inada Y. Thrombin-catalyzed conversion of fibrinogen to fibrin. J Biochem 1972; 71: 897-899
    CrossrefPubMedGoogle Scholar
  • 33 Ohlsson K. Comparison of affinity of trypsin for two a-macroglobulin fractions and for arantitrypsin in dog serum. Clin Chim Acta 1971; 32: 215-220
    CrossrefPubMedGoogle Scholar
  • 34 Gitel SN, Wessler S. The antithrombotic effects of warfarin and heparin following infusions of tissue thromboplastin in rabbits: Clinical implications. J Lab Clin Med 1979; 94: 481-488
    PubMedGoogle Scholar
  • 35 Colman RW, Marder VJ. Disseminated intravascular coagulation (DIC): Pathogenesis, pathophysiology, and laboratory anomalies. In: Hemostasis and Thrombosis Basic Principles and Clinical Practice. Colman RW, Hirsh J, Marder VJ, Salzman EW. (eds.) J B Lippincott Company; Philadelphia, Toronto: 1982
    Google Scholar
  • 36 Marder VJ, Martin SE, Colman RW. Clinical aspects of consumptive thrombohemorrhagic disorders. In: Hemostasis and Thrombosis. Basic Principles and Clinical Practice. Colman RW, Hirsh J, Marder VJ, Salzman EW. (eds. J B Lippincott Company; Philadelphia, Toronto: 1982
    Google Scholar
  • 37 Osterud B, Rapaport SI. Activation of factor IX by the reaction product of tissue factor and factor VII: additional pathway for initiating blood coagulation. Proc Nat Acad Sci USA 1977; 74: 5260-5264
    CrossrefPubMedGoogle Scholar
  • 38 Jesty J, Silverberg SA. Kinetics of the tissue factor-dependent activation of coagulation factors IX and X in a bovine plasma system. J Biol Chem 1979; 254: 12337-12345
    PubMedGoogle Scholar
  • 39 Jesty J, Morrison SA. The activation of factor IX by tissue factor -factor VII in a bovine plasma system lacking factor X. Thromb Res 1983; 32: 171-181
    CrossrefPubMedGoogle Scholar
  • 40 Marlar RA, Kleiss AJ, Griffin JH. An alternative extrinsic pathway of human blood coagulation. Blood 1982; 60: 1353-1358
    PubMedGoogle Scholar
  • 41 Penick GD, Roberts HR, Webster WP, Brinkhous KM. The prevention of hemorrhage with anticoagulants - An exploratory study of a paradox. Ann N Y Acad Sci 1964; 115: 67-77
    PubMedGoogle Scholar
  • 42 Owen CA, Bowie EJ W. Effect of heparin on chronically induced intravascular coagulation in dogs. Am J Physiol 1975; 229: 445-454
    PubMedGoogle Scholar
  • 43 Hoie J, Schenk WG. Impact of disseminated intravascular coagulation on central hemodynamics, and cardiac performance: An experimental study in dogs. Surgery 1971; 70: 685-92
    PubMedGoogle Scholar
  • 44 Bergentz SE, Ljungqvist U, Levis DH. The distribution of platelets, fibrin and erythrocytes in various organs following thrombin infusion: An experimental study in dogs with and without antifibrinolytic therapy. Surgery 1972; 71: 190-195
    PubMedGoogle Scholar
  • 45 Hoie J, Schenk WG. Experimental intravascular coagulation: Impairment of renal blood flow following thrombin infusion in the dog. J Trauma 1972; 12: 302-308
    CrossrefPubMedGoogle Scholar
  • 46 Hoie J, Schenk WG. Pulmonary hemodynamics and function in acute experimental disseminated intravascular coagulation. J Trauma 1973; 13: 887-894
    CrossrefPubMedGoogle Scholar
  • 47 Olsson P, Swedenborg J, Lindquist O. Effects of slow defibrinogena-tion on the canine lung. J Trauma 1974; 14: 325-329
    CrossrefPubMedGoogle Scholar
  • 48 Josephson S, Swedenborg J, Dahlgren SE. Delayed lung lesion in dogs after thrombin-induced disseminated intravascular coagulation. Acta Chir Scand 1974; 140: 431-435
    PubMedGoogle Scholar
  • 49 Jastrzebski J, Amot RN, Hilgard P, Sykes MK. Thrombin-induced disseminated intravascular coagulation in the dog: I. Demonstration of microthrombin in the lung. Br J Anaesth 1975; 47: 654-657
    CrossrefPubMedGoogle Scholar
  • 50 Jastrzebski J, Hilgard P, Chakrabarti MK, Henry K, Sykes MK. Thrombin-induced disseminated intravascular coagulation in the dog. II. Cardiorespiratory changes during spontaneous and controlled ventilation. Br J Anesth 1975; 47: 658-666
    CrossrefPubMedGoogle Scholar
  • 51 Garner R, Evensen SA. Endotoxin-induced intravascular coagulation and shock in dogs: The role of factor VII. Br J Haematol 1974; 27: 655-668
    CrossrefPubMedGoogle Scholar
  • 52 Garner R, Chater BV, Brown DL. The role of complement in endotoxin shock and disseminated intravascular coagulation: Experimental observations in the dog. Br J Haematol 1974; 28: 393-401
    CrossrefPubMedGoogle Scholar
  • 53 Miiller-Berghaus G, Niepoth M, Rabens-Alles B, Rump E, Murano G. Antithrombin III concentration and antithrombin III substitution in experimental disseminated intravascular coagulation. Thromb Haemostas 1983; 50: 323
    PubMedGoogle Scholar
  • 54 Hogg DH, Blomback B. The specificity of the fibrinogen-thrombin reaction. Thromb Res 1974; 5: 685-693
    CrossrefPubMedGoogle Scholar
  • 55 Nossel HL, Ti M, Kaplan KL, Spanondis K, Soland T, Butler VP. The generation of fibrinopeptide A in clinical blood samples. Evidence for thrombin activity. J Clin Invest 1976; 58: 1136-1144
    CrossrefPubMedGoogle Scholar
  • 56 Walker FJ, Esmon CT. Interactions between heparin and factor Xa. Inhibition of prothrombin activation. Biochim Biophys Acta 1979; 405-415
    PubMedGoogle Scholar
  • 57 Ofosu FA, Cerskus AL, Hirsh J, Smith LM, Modi GJ, Blajchman MA. The inhibition of the anticoagulant activity of heparin by platelets, brain phospholipids and tissue factor. Br J Haematol 1984; 57: 229-238
    CrossrefPubMedGoogle Scholar
  • 58 Teitel JM, Rosenberg RD. Protection of factor Xa from neutralization by the heparin-antithrombin complex. J Clin Invest 1983; 71: 1383-1391
    CrossrefPubMedGoogle Scholar
  • 59 Wiman B, Collen D. On the kinetics of the reaction between human antiplasmin and plasmin. Eur J Biochem 1978; 84: 573-578
    CrossrefPubMedGoogle Scholar
  • 60 Nanninga LB. Molar concentrations of fibrinolytic components, especially free fibrinolysin, in vivo. Thrombos Diathes Haemorrh 1975; 33: 244-255
    PubMedGoogle Scholar
  • 61 Bickford AF, Faylor FB, Sheena R. Inhibition of the fibrinogen-plasmin reaction by p-aminocarboxylic acids and alkylamines. Biochim Biophys Acta 1964; 92: 328-333
    PubMedGoogle Scholar
  • 62 Griffith MJ. The heparin-enhanced antithrombin Ill/thrombin reaction is saturable with respect to both thrombin and antithrombin III. J Biol. Chem 1982; 267: 13899-13902
    PubMedGoogle Scholar